2017, Número 2
<< Anterior Siguiente >>
Ann Hepatol 2017; 16 (2)
Drug-induced Liver Injury Caused by Ipragliflozin Administration with Causality Established by a Positive Lymphocyte Transformation Test (LTT) and the Roussel Uclaf Causality Assessment Method (RUCAM): A Case Report
Niijima K, Niijima Y, Okada S, Yamada M
Idioma: Ingles.
Referencias bibliográficas: 9
Paginas: 308-311
Archivo PDF: 113.94 Kb.
RESUMEN
Sin resumen.
REFERENCIAS (EN ESTE ARTÍCULO)
Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-25.
Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-19.
Yilmaz Y, Younossi ZM. Obesity-Associated Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2014; 18: 19-31.
Parveen R, Agarwal NB, Kaushal N, Mali G, Raisuddin S. Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials. Expert Opin Pharmacother 2016; 17: 105-15.
Pichler WJ. Lymphocyte transformation test. Encyclopedia of Immunology 2014; 10.1007/978-3-642-27786-3_924-5
Honda Y, Imajo K, Kato T, Kessoku T, Ogawa Y, Tomeno W, Kato S, et al. The selective SGLT2 inhibitor Ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice. PLoS ONE 2016; 11: e0146337. doi:10.1371/ journal.pone.0146337
Danan G, Teschke R. RUCAM in drug and herb induced liver injury: The Update. Int J Mol Sci. 2015; Dec 24;17(1). pii: E14. doi: 10.3390/ijms17010014.
Teschke R, Danan G. Diagnosis and Management of Drug- Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease. Drug Saf 2016; 39: 729-44.
Tarantino G, Conca P, Basile V, Gentile A, Capone D, Polichetti G, Leo E. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res 2007; 37: 410-15.
Texto completo
Cómo citar este artículo